Published: August 2009

Etanercept and uveitis

Prescriber Update 30(3): 18
August 2009

Etanercept (Enbrel) is a TNFα inhibitor indicated for the treatment of rheumatoid arthritis, ankylosing spondolitits, juvenile idiopathic arthritis, psoriasis and psoriatic arthritis.

A review of spontaneous post-marketing reports submitted to CARM indicated that there may be a risk of uveitis associated with the use of etanercept.

This association has been considered by the Medicines Adverse Reaction Committee (MARC) and has resulted in the Enbrel datasheet being updated to include uveitis as an uncommon adverse reaction. The Enbrel data sheet is available at